长春高新子公司褪黑素颗粒上市申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in the approval process for this product [1][1]. Group 1 - Jinsai Pharmaceutical's melatonin granules are developed for the pediatric neuropsychiatric field and classified as a Class 4 chemical drug [1]. - The product is designed to activate the MT1 and MT2 receptors in the suprachiasmatic nucleus, which regulates neural activity and demonstrates sleep-inducing effects [1]. - The intended use of the melatonin granules is to improve sleep difficulties associated with neurodevelopmental disorders in children [1].